Literature DB >> 20981164

Collagenous and non-collagenous biochemical markers of bone metastases from prostate cancer.

A Zafeirakis1.   

Abstract

The importance of the bone microenvironment to the pathophysiology and morbidity associated with prostate cancer bone metastasis is becoming increasingly apparent. Significant alterations take place in the microenvironment of bone, which disturb the normal coupling that exists between bone resorption and bone formation. Consequently, a better understanding of the mechanisms that interact at the molecular level will definitely result in more effective therapy for patients with this devastating complication of prostatic carcinoma. This review will discuss the diagnostic and predictive implications of various collagenous and non-collagenous bone markers, along with the novel markers of osteoclastogenesis and other matrix enzymes such as metalloproteinases and growth factors responsible for the complex biochemical mechanisms that upregulate bone resorption/formation during the development of metastasis. Further prospective studies are needed to determine whether any of these markers measured longitudinally in prostate cancer patients without bone scan evidence of skeletal disease will ultimately predict those patients who will develop bone metastases from their malignancy. Nonetheless, from the clinical point of view it is important to know that these novel markers carry the potential to provide meaningful information for daily practice by using upper normal reference values as cut-offs for identifying patients with an increased risk of developing progressive bone disease or skeletal related events.

Entities:  

Keywords:  Prostate cancer; RANKL; bone metastases; bone turnover markers; osteoprotegerin; review; type I collagen

Year:  2010        PMID: 20981164      PMCID: PMC2943353     

Source DB:  PubMed          Journal:  Hippokratia        ISSN: 1108-4189            Impact factor:   0.471


  63 in total

1.  Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer.

Authors:  Masanori Noguchi; Jyunro Yahara; Shinshi Noda
Journal:  Urology       Date:  2003-05       Impact factor: 2.649

Review 2.  The amino- and carboxyterminal cross-linked telopeptides of collagen type I, NTX-I and CTX-I: a comparative review.

Authors:  Markus Herrmann; Markus J Seibel; Markus Seibel
Journal:  Clin Chim Acta       Date:  2008-03-27       Impact factor: 3.786

3.  Targeting of bone-derived insulin-like growth factor-II by a human neutralizing antibody suppresses the growth of prostate cancer cells in a human bone environment.

Authors:  Taichi Kimura; Takeshi Kuwata; Satoshi Ashimine; Manabu Yamazaki; Chisako Yamauchi; Kanji Nagai; Akashi Ikehara; Yang Feng; Dimiter S Dimitrov; Seiichi Saito; Atsushi Ochiai
Journal:  Clin Cancer Res       Date:  2009-12-22       Impact factor: 12.531

4.  Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer.

Authors:  Mitsuru Koizumi; Junji Yonese; Iwao Fukui; Etsuro Ogata
Journal:  J Urol       Date:  2002-04       Impact factor: 7.450

5.  Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer.

Authors:  Azizbek Ramankulov; Michael Lein; Glen Kristiansen; Stefan A Loening; Klaus Jung
Journal:  Prostate       Date:  2007-02-15       Impact factor: 4.104

6.  Predictive implications of bone turnover markers after palliative treatment with (186)Re-HEDP in hormone-refractory prostate cancer patients with painful osseous metastases.

Authors:  Athanasios Zafeirakis; Georgios Papatheodorou; Athanasios Arhontakis; Athanasios Gouliamos; Lambros Vlahos; Georgios S Limouris
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

Review 7.  The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis.

Authors:  A John; G Tuszynski
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

8.  Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid.

Authors:  Allan Lipton; Richard Cook; Fred Saad; Pierre Major; Patrick Garnero; Evangelos Terpos; Janet E Brown; Robert E Coleman
Journal:  Cancer       Date:  2008-07-01       Impact factor: 6.860

Review 9.  RANKL/RANK/OPG: key therapeutic target in bone oncology.

Authors:  Kosei Ando; Kanji Mori; Francoise Rédini; Dominique Heymann
Journal:  Curr Drug Discov Technol       Date:  2008-09

Review 10.  RANKL inhibition in the treatment of bone metastases.

Authors:  Allan Lipton; Susie Jun
Journal:  Curr Opin Support Palliat Care       Date:  2008-09       Impact factor: 2.302

View more
  1 in total

1.  Endochondral Ossification Induced by Cell Transplantation of Endothelial Cells and Bone Marrow Stromal Cells with Copolymer Scaffold Using a Rat Calvarial Defect Model.

Authors:  Zhe Xing; Xiaofeng Jiang; Qingzong Si; Anna Finne-Wistrand; Bin Liu; Ying Xue; Kamal Mustafa
Journal:  Polymers (Basel)       Date:  2021-05-09       Impact factor: 4.329

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.